Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
about
The role of B cells in solid organ transplantation.The evolving role of alemtuzumab (Campath-1H) in renal transplantation.Immune profile of pediatric renal transplant recipients following alemtuzumab induction.Developments in clinical islet, liver thoracic, kidney and pancreas transplantation in the last 5 years.Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques.Mycophenolate mofetil and sirolimus combination in renal transplantation.Can mTOR inhibitors reduce the risk of late kidney allograft failure?Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.Neglected respiratory toxicity caused by cancer therapy.Current landscape for T-cell targeting in autoimmunity and transplantation.Prognostic significance of graft Foxp3 expression in renal transplant recipients: a critical review and attempt to reconcile discrepancies.Advances in pharmacotherapy to treat kidney transplant rejection.An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.Bilateral hand transplantation: result at 20 months.Alemtuzumab induction therapy in solid organ transplantation.Antibody induction therapy in adult kidney transplantation: A controversy continues.Use of mTOR inhibitors in human organ transplantation.Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells.Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.Weight-based dosing of alemtuzumab: an ounce of prevention?Cancer risk with alemtuzumab following kidney transplantation.Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy.Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients.Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q33891696-B272D797-6BB2-4137-ADB4-73C928C9EB10Q34613973-77AF9A5F-B458-457F-ACFB-51C3ABEC773DQ35720801-9C957277-75FD-43BD-92ED-F787DB244242Q36505718-D7741D3B-87E8-4047-A606-523DC4CF4FFFQ36575860-371ADFAD-494D-42E4-B9C7-5122CC4F69F3Q36575992-7A55081D-B9C6-4A37-A32C-81B54AC3D06FQ36884566-02C929CF-C26B-45E7-A4B3-7E24F2399865Q36906347-5DA28C89-F3A2-4100-B959-F830EC85BB28Q37064446-8C32EA9B-FBD2-4579-A026-B4C56B7221F5Q37429804-2DA6066A-6F62-4DCE-A2BE-BF456AA546D6Q37900647-1821139C-4970-4FCF-AF50-4806AB9C408BQ38069412-F243066F-B63C-46D3-B15F-7C0EF8D0E5BCQ38544529-03B90F64-7328-4F18-B396-D910B9D46D66Q40200912-23178420-B568-4E68-8588-D9B7073BB375Q41897278-F6C3FC44-3A18-4795-8DFB-D70A2030CE79Q42150369-2D961130-092E-444F-866F-4853277CE284Q42452829-A5A34812-F414-4030-9BB0-26D28D00D6FBQ42876591-2FCE79AA-F916-47B9-9B81-AC457A9035E6Q42969608-F5283E8A-D8BD-40E2-A692-29C9CC8BD442Q43061556-E3C09A13-6196-4B96-A10D-FD27BCB394FFQ46569157-5122FA01-FC97-471D-9144-D831615DDBBCQ46797116-408EADFA-A045-476D-8ABD-B7427F2575BAQ47209893-B4F28294-BEE8-4387-AA00-AB7F342DF54AQ50866852-3740653A-FAD4-40C6-B83F-2D924CC63032Q51749477-28004B51-A7F2-49E8-9362-71ABD2E44D23Q53595595-20B4F27C-3B45-4011-A15E-C4F5D6A13B3AQ53861449-9A4A7B3E-0B7E-4FB9-A9A1-71B69926F0F8Q54687845-0C207FE6-7843-4C25-9B89-57100CA7017AQ58805821-3EF0D9AB-92AB-40FF-9FE1-ECF216C48FEF
P2860
Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Alemtuzumab induction and siro ...... transplant immunosuppression.
@en
Alemtuzumab induction and siro ...... transplant immunosuppression.
@nl
type
label
Alemtuzumab induction and siro ...... transplant immunosuppression.
@en
Alemtuzumab induction and siro ...... transplant immunosuppression.
@nl
prefLabel
Alemtuzumab induction and siro ...... transplant immunosuppression.
@en
Alemtuzumab induction and siro ...... transplant immunosuppression.
@nl
P2093
P1476
Alemtuzumab induction and siro ...... transplant immunosuppression.
@en
P2093
B Mastroianni
D Goldfarb
H R Ismail
J Brockmann
M Simmonds
M Zilvetti
P304
P356
10.1111/J.1600-6143.2005.01123.X
P407
P577
2005-12-01T00:00:00Z